Hormonal
Anti-obesity medication (AOM) administered in primary care settings produces approximately double the weight loss compared to lifestyle interventions alone, achieving an additional ~3 kg reduction.
If you are working with a primary care provider to lose weight, adding an FDA-approved anti-obesity medication to your lifestyle plan can roughly double your weight loss results compared to lifestyle changes alone. However, be prepared for the possibility that you may need to stay on the medication long-term to maintain the loss, as weight regain is common when stopping treatment.
Interventions that included a medication component (alone or as part of a multipronged intervention) achieved a greater weight reduction by −2.94 kg (p < 0.0001).
Why this rating
Meta-analysis of 7 RCTs, but with substantial heterogeneity (I2=86%) and publication bias.
Source
A closer look at weight loss interventions in primary care: a systematic review and meta-analysis
Leigh Perreault et al. · Frontiers in Medicine · 2023
DOI 10.3389/fmed.2023.1204849
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →